{"title": "A study to assess the safety and efficacy of \"pHoxvedic\", an ayurvedic nasal drop in prevention COVID-19 infection in healthy high-risk healthcare professionals", "author": "RAPHAEL LABS LTD", "url": null, "hostname": null, "description": null, "sitename": null, "date": "2021-04-22", "cleaned_text": "A study to assess the safety and efficacy of \"pHoxvedic\", an ayurvedic nasal drop in prevention COVID-19 infection in healthy high-risk healthcare professionals CTRI; 22-04-2021; TrialID: CTRI/2021/04/032989 Clinical refers as \u00c3\u00a2\u00e2?\u00ac\u00c5?pHoxvedic\u00c3\u00a2\u00e2?\u00ac? is unique combination of rationally selected 6 [salts]and 4 [essential oils]. pHoxvedic should be taken TID 140 ul/nostril for 45 days, with a gap of 6-8 hours between doses. Control Intervention1 Placebo Ayurvedic Nasal Drop Placebo is composed Chloride], [Polyethylene glycol]400, [Basil]Delight 2010 and Sterile [water]. Placebo should be taken TID 140 ul/nostril for 45 days, with a gap of 6-8 hours between doses. Primary Percentage of subjects outcome: [who]test positive on rt-PCR for [SARS-CoV]-2Timepoint Over 45 days of the study CriteriaInclusion criteria 1. [Healthcare]professionals at high [risk]of [SARS-CoV-2]exposure. 2. Normal or clinically insignificant findings during [screening], medical [history], [medical examination], [laboratory]evaluations. 3. Subjects agree to refrain from taking over the counter products intended to prevent, intervene in, or treat colds/flu, starting at study entry and continuing through out study. 4. Able to give voluntary [informed consent]for participation in the study. Exclusion criteria 1. [Laboratory]confirmed 2. [Laboratory]confirmed ( [PCR] any [clinical trial]of a [SARS-CoV-2]candidate [vaccine]. 5. Subjects, [who]have been partially or fully vaccinated against SARS-CoV2 with any approved [vaccine]. 6. [History]of [thrombocytopenia]or any coagulation disorder, or subjects on [therapy]. 7. Subjects with confirmed immunosuppressive or immunodeficiency disorder; or subjects on any immunosuppressive or [immunostimulant] [therapy]. 8. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, hematological, psychiatric, or immunological disorder or any other symptoms or disorder that may interfere with study objectives as per Principal [Investigator]discretion. 9. Subjects administered [blood], [blood]containing products or [immunoglobulins]within the last 3 months or planned [administration] during the study. 10. SARS-CoV-2 vaccine planned to be administered during the study period 11. Pregnant and lactating [women]. 12. Participation in another [clinical trial]in the past 3 months. 13. [History]of [drug]/ [alcohol abuse]. 14. Unable to complete the daily symptom tracker. 15. Unable/unwilling to follow local standard SARS-CoV-2 infection prevention [measures]e.g., PPE, [face]shield, [masks]etc. [will]make use of the [nasal spray]difficult or is symptomatic to the point where it [will]interfere with the study. Collection: Clinical trial registers Database: ICTRP Topics: Traditional medicine / Vaccines Year: Clinical Trial Register Similar MEDLINE ... LILACS LIS "}